Abstract
Despite their widespread Internet availability and use, many of the new drugs of abuse remain unfamiliar to health care providers. The herbal marijuana alternatives, like K2 or Spice, are a group of herbal blends that contain a mixture of plant matter in addition to chemical grade synthetic cannabinoids. The synthetic cathinones, commonly called “bath salts,” have resulted in nationwide emergency department visits for severe agitation, sympathomimetic toxicity, and death. Kratom, a plant product derived from Mitragyna speciosa Korth, has opioid-like effects, and has been used for the treatment of chronic pain and amelioration of opioid-withdrawal symptoms. Salvia divinorum is a hallucinogen with unique pharmacology that has therapeutic potential but has been banned in many states due to concerns regarding its psychiatric effects. Methoxetamine has recently become available via the Internet and is marked as “legal ketamine.” Moreover, the piperazine derivatives, a class of amphetamine-like compounds that includes BZP and TMFPP, are making a resurgence as “legal Ecstasy.” These psychoactives are available via the Internet, frequently legal, and often perceived as safe by the public. Unfortunately, these drugs often have adverse effects, which range from minimal to life-threatening. Health care providers must be familiar with these important new classes of drugs. This paper discusses the background, pharmacology, clinical effects, detection, and management of synthetic cannabinoid, synthetic cathinone, methoxetamine, and piperazine exposures.
Similar content being viewed by others
References
European Monitoring Centre for Drugs and Addiction-Europol (2011) 2010 Annual Report on the implementation of Council Decision 2005/387/JHA. http://www.emcdda.europa.eu/attachements.cfm/att_132857_EN_EMCDDA-Europol%20Annual%20Report%202010A.pdf. Accessed 1 May 2011
Zawilska JB (2011) “Legal highs”—new players in the old drama. Curr Drug Abuse Rev 4(2):122–130
Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44(5):832–837
Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM (2010) The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118(1–3):309–310
Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K (2009) Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 106(27):464–467
Sobolevsky T, Prasolov I, Rodchenkov G (2010) Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 200(1–3):141–147
Huffman JW (2005) CB2 receptor ligands. Mini Rev Med Chem 5(7):641–649
Mazzoni O, Diurno MV, di Bosco AM, Novellino E, Grieco P, Esposito G et al (2010) Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents. Chem Biol Drug Des 75(1):106–114
Pavlopoulos S, Thakur GA, Nikas SP, Makriyannis A (2006) Cannabinoid receptors as therapeutic targets. Curr Pharm Des 12(14):1751–1769
Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ et al (2008) Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A 105(26):9099–9104
Poso A, Huffman JW (2008) Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br J Pharmacol 153(2):335–346
Marriott KS, Huffman JW (2008) Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem 8(3):187–204
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR et al (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62(4):588–631
European Monitoring Centre for Drugs and Drug Addiction, Lisbon (2009) http://www.emcdda.europa.eu/html.cfm/index90917EN.html. Accessed 11 Jan 2010
Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L et al (2009) Spice: a never ending story? Forensic Sci Int 191(1–3):58–63
Zuba D, Byrska B, Maciow M (2011) Comparison of “herbal highs” composition. Anal Bioanal Chem 400(1):119–126
Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN et al (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83(11):4228–4236
Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011) CP47,497-C8 and JWH073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659(2–3):139–145
Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198(1–3):31–38
Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160(3):585–593
Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 57(4):439–441
Piggee C (2009) Investigating a not-so-natural high. Anal Chem 81(9):3205–3207
Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 49(8):760–764
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3(9):771–784
McLachlan G (2009) Taking the spice out of legal smoking mixtures. Lancet 374(9690):600
Scalzo A (2010) K2 synthetic marijuana use among teenagers—Missouri, 2010. The Epidemic Information Exchange, Missouri
Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M et al (2011) Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 879(15–16):1126–1136
US Department of Justice Drug Enforcement Administration (2011) Scheduling update. Microgram Bulletin 44(1):1–4
Sumnall HR, Evans-Brown M, McVeigh J (2011) Social, policy, and public health perspectives on new psychoactive substances. Drug Test Anal 3(7–8):515–523
Schifano F, Ricciardi A, Corazza O, Deluca P, Davey Z, Rafanelli C (2010) New drugs of abuse on the web: the role of the psychonaut web mapping project. Riv Psichiatr 45(2):88–93
Hu X, Primack BA, Barnett TE, Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16
Johnson LA, Johnson RL, Alfonzo C (2011) Spice: a legal marijuana equivalent. Mil Med 176(6):718–720
Berge KH, Bush DM (2010) The subversion of urine drug testing. Minn Med 93(8):45–47
Vardakou I, Pistos C, Spiliopoulou C (2010) Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197(3):157–162
Richter P, Caraballo R, Pederson LL, Gupta N (2008) Exploring use of nontraditional tobacco products through focus groups with young adult smokers, 2002. Prev Chronic Dis 5(3):A87
Schifano F, Deluca P, Baldacchino A, Peltoniemi T, Scherbaum N, Torrens M et al (2006) Drugs on the web; the psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 30(4):640–646
Mustata C, Torrens M, Pardo R, Perez C, Farre M (2009) Spice drugs: cannabinoids as a new designer drugs. Adicciones 21(3):181–186
Community Epidemiology Work Group/National Institute on Drug Abuse (2010) Epidemiologic trends in drug abuse. http://www.nida.nih.gov/PDF/CEWG/vol1_610.pdf. Accessed 23 June 2011
Wells DL, Ott CA (2011) The “new” marijuana. Ann Pharmacother 45(3):414–417
Ashton CH, Moore PB (2009) Regulation of synthetic cannabinoids. Lancet 374(9701):1595
Tylden E, Wild D (1967) A case for cannabis? Br Med J 3(5564):556
Dowling G, Regan L (2011) A method for CP 47, 497 a synthetic non-traditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(3–4):253–259
Thakur GA, Nikas SP, Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5(7):631–640
Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI et al (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. J Anal Toxicol 34(5):252–260
Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwarter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45(10):1186–1194
Chin CN, Murphy JW, Huffman JW, Kendall DA (1999) The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther 291(2):837–844
Brown SM, Wager-Miller J, Mackie K (2002) Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 1576(3):255–264
Morgan NH, Stanford IM, Woodhall GL (2009) Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57(4):356–368
Verdurand M, Dalton VS, Zavitsanou K (2010) GABA(A) receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Res 1351:238–245
Napchan U, Buse DC, Loder EW (2011) The use of marijuana or synthetic cannabinoids for the treatment of headache. Headache 51(3):502–505
Ameri A, Wilhelm A, Simmet T (1999) Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br J Pharmacol 126(8):1831–1839
Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P (2008) CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153(2):347–357
Rajesh M, Mukhopadhyay P, Hasko G, Pacher P (2008) Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 377(4):1248–1252
Lombard C, Nagarkatti M, Nagarkatti P (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122(3):259–270
Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S et al (2009) Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4(6):e5844
Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P et al (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 23(7):2120–2130
Filbert MG, Forster JS, Smith CD, Ballough GP (1999) Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures. Ann N Y Acad Sci 890:505–514
Biegon A, Joseph AB (1995) Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol Res 17(4):275–280
Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 283(1–3):19–29
Biegon A (1995) Neuroprotective activity of HU-211, a novel nonpsychotropic synthetic cannabinoid. Ann N Y Acad Sci 765:314
Schneir AB, Cullen J, Ly BT (2011) “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 40(3):296–299
Vearrier D, Osterhoudt KC (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26(6):462–465
Benford DM, Caplan JP (2011) Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 52(3):295
Every-Palmer S (2010) Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 105(10):1859–1860
Wada M, Yamahara K, Ikeda R, Kikura-Hanajiri R, Kuroda N, Nakashima K (2012) Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs. Biomed Chromatogr 26(1):21–25
Teske J, Weller JP, Fieguth A, Rothamel T, Schulz Y, Troger HD (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878(27):2659–2663
El-Subbagh H, Wittig T, Decker M, Elz S, Nieger M, Lehmann J (2002) Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands. Arch Pharm (Weinheim) 335(9):443–448
Fisar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381(6):563–572
Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwarter V (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 46(2):163–171
ElSohly MA, Gul W, Elsohly KM, Murphy TP, Madgula VL, Khan SI (2011) Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 35(7):487–495
Moller I, Wintermeyer A, Bender K, Jubner M, Thomas A, Krug O et al (2011) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3(9):609–620
Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 400(1):79–88
NMS labs (2011) NMS Labs Online Test Catalog. http://www.nmslabs.com/services-forensic-K2-ELISA-FAQ. Accessed 30 Oct 2011
Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of “spice” exposure. Clin Toxicol (Phila) 49(5):431–433
Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58(4):322–328
Justinova Z, Tanda G, Munzar P, Goldberg SR (2004) The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 173(1–2):186–194
Hammersley R (2010) Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 105(2):373
Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P (1990) Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 30(6):825–828
Al-Hebshi NN, Skaug N (2005) Khat (Catha edulis)-an updated review. Addict Biol 10(4):299–307
World Health Organization Expert Committee on Drug Dependence (2006) Assessment of Khat (Catha edulis Forsk). http://www.who.int/medicines/areas/quality_safety/4.4KhatCritReview.pdf. Accessed 25 Oct 2011
US Drug Enforcement Administration (2011) Methcathinone. http://www.justice.gov/dea/concern/methcathinone.html. Accessed 17 July 2011
McElrath K, O’Neill C (2011) Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. The Intern J Drug Policy 22(2):120–127
Winstock A, Mitcheson L, Ramsey J, Marsden J (2011) Mephedrone: use, subjective effects and health risks. Addiction 106(11):1991–1996
American Association of Poison Control Centers (2011) Bath salts data. http://www.aapcc.org/dnn/Portals/0/Bath%20Salts%20Data%20for%20Website%207.07.2011.pdf. Accessed 19 July 2011
US Department of Justice DEA (2011) Request for information on synthetic cathinones. Micr Bull 44(4):31–34
US Department of Justice Drug Enforcement Administration (2011) Notice of intent—scheduled of controlled substances: temporary placement of three synthetic cathinones into schedule I. Micr Bull 44(9):57–65
Drug Enforcement Agency (2004) “Cleopatra's mini bath tablets passion” containing Dove logo MDA tablets and “Cleopatra's exotic bath salts passion” containing “Ice” methamphetamine from Vancouver, British Columbia. Micr Bull 37(4)
US Department of Justice DEA (2011) Request for information on synthetic cathinones. Micr Bull April 2011 Contract No. 4
Goodnough A, Zezima K (2011) An alarming new stimulant, legal in many states. The New York Times, July 16, 2011
Heller D (2011) Autopsy: man died from “bath salts”. http://www.myfoxtampabay.com/dpp/news/local/hillsborough/autopsy-man-died-from-bath-salts-06022011. Accessed 16 July 2011
Larsen D (2011) 2 more suspected bath salt deaths investigated. Dayton Daily News, June 17th, 2011
Morgan PL, Fuchs D, Compton DL, Cordray DS, Fuchs LS (2008) Does early reading failure decrease children's reading motivation? J Learn Disabil 41(5):387–404
Centers for Disease Control and Prevention (2011) Emergency department visits after use of a drug sold as “bath salts”—Michigan, November 13, 2010–March 31, 2011. MMWR 60(19):624–627
Gibbons S, Zloh M (2010) An analysis of the ‘legal high’ mephedrone. Bioorganic Med Chem Lett 20(14):4135–4139
European Monitoring Centre for Drugs and Addiction (2011) Drug Profiles—Synthetic cathinones. http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones. Accessed 10 July 2011
Wood DM, Greene SL, Dargan PI (2011) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J: EMJ 28(4):280–282
Dargan PI, Albert S, Wood DM (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM: Monthly J Assoc Physician 103(11):875–879
World Health Organization Expert Committee on Drug Dependence (2006) Assessment of Khat (Catha edulis Forsk). World Health Organization Expert Committee on Drug Dependence 34th meeting, Geneva
Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381(1):63–69
Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559(2–3):132–137
Olives T, Orozeo B, Stellpflug S (2011) Bath salts update: meow meow and MTV. ACEP Toxiciology Section Newsletter
Erowid Vaults (2011) 4-MethylMethcathinone/mephedrone. http://www.erowid.org/chemicals/4_methylmethcathinone/. Accessed 16 July 2011
Erowid Vaults (2011) Methylone. http://www.erowid.org/chemicals/methylone/methylone.shtml. Accessed 16 July 2011
Erowid Vaults (2011) MDPV. http://www.erowid.org/chemicals/mdpv/mdpv.shtml. Accessed 16 July 2011
Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397(3):1225–1233
American Association of Poison Control Centers (2010) US Poison Centers raise alarm about toxic substance marketed as bath salts. http://www.aapcc.org/dnn/Portals/0/prrel/bathsalts-final.pdf. Accessed 15 July 2011
Byrd S (2011) Officials fear bath salts becoming the next big drug menace. The Washington Post 23:2011
James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP et al (2010) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 28(8):686–689
Synthetic cathinone derivatives. In: POISINDEX® System [Internet database]. Thomson Reuters (Healthcare) Inc. Accessed 20 July 2011
Nicholson PJ, Quinn MJ, Dodd JD (2010) Headshop heartache: acute mephedrone ‘meow’ myocarditis. Heart 96(24):2051–2052
Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202(1–3):e62–e63
Sparago M, Wlos J, Yuan J, Hatzidimitriou G, Tolliver J, Dal Cason TA et al (1996) Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J Pharmacol Exp Ther 279(2):1043–1052
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18(20):8417–8422
NMS labs (2011) NMS Labs Online Test Catalog. http://www.nmslab.com/services-forensic-designer-stimulants-testing. Accessed 8 Nov 2011
Assanangkornchai S, Muekthong A, Sam-Angsri N, Pattanasattayawong U (2007) The use of mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Subst Use Misuse 42(14):2145–2157
Arndt T, Claussen U, Gussregen B, Schrofel S, Sturzer B, Werle A et al (2011) Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Sci Int 208(1–3):47–52
Harizal SN, Mansor SM, Hasnan J, Tharakan JK, Abdullah J (2010) Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in rodent. J Ethnopharmacol 131(2):404–409
Kumarnsit E, Keawpradub N, Nuankaew W (2007) Effect of Mitragyna speciosa aqueous extract on ethanol withdrawal symptoms in mice. Fitoterapia 78(3):182–185
Vicknasingam B, Narayanan S, Beng GT, Mansor SM (2010) The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 21(4):283–288
Jansen KL, Prast CJ (1988) Psychoactive properties of mitragynine (Kratom). J Psychoactive Drugs 20(4):455–457
Babu KM, McCurdy CR, Boyer EW (2008) Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila) 46(2):146–152
Schmidt MM, Sharma A, Schifano F, Feinmann C (2011) “Legal highs” on the net-evaluation of UK-based websites, products and product information. Forensic Sci Int 206(1–3):92–97
Boyer EW, Babu KM, Macalino GE (2007) Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict 16(5):352–356
Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH (2008) Self-treatment of opioid withdrawal using Kratom (Mitragynia speciosa Korth). Addiction 103(6):1048–1050
Chittrakarn S, Keawpradub N, Sawangjaroen K, Kansenalak S, Janchawee B (2010) The neuromuscular blockade produced by pure alkaloid, mitragynine and methanol extract of Kratom leaves (Mitragyna speciosa Korth.). J Ethnopharmacol 129(3):344–349
Phongprueksapattana S, Putalun W, Keawpradub N, Wungsintaweekul J (2008) Mitragyna speciosa: hairy root culture for triterpenoid production and high yield of mitragynine by regenerated plants. Z Naturforsch C 63(9–10):691–698
Shellard EJ (1974) The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull Narc 26(2):41–55
Leon F, Habib E, Adkins JE, Furr EB, McCurdy CR, Cutler SJ (2009) Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Nat Prod Commun 4(7):907–910
Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Sakai S et al (1998) Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sci 62(16):1371–1378
Matsumoto K, Mizowaki M, Suchitra T, Takayama H, Sakai S, Aimi N et al (1996) Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Life Sci 59(14):1149–1155
Matsumoto K, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N et al (1996) Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 317:75–81
Matsumoto K, Yamamoto LT, Watanabe K, Yano S, Shan J, Pang PK et al (2005) Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci 78(2):187–194
Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, Ponglux D et al (2005) Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci 78(1):2–7
de Moraes NV, Moretti RA, Furr EB 3rd, McCurdy CR, Lanchote VL (2009) Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 877(24):2593–2597
Maruyama T, Kawamura M, Kikura-Hanajiri R, Takayama H, Goda Y (2009) The botanical origin of Kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J Nat Med 63(3):340–344
Idayu NF, Hidayat MT, Moklas MA, Sharida F, Raudzah AR, Shamima AR et al (2011) Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytomedicine 18(5):402–407
Adkins JE, Boyer EW, McCurdy CR (2011) Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr Top Med Chem 11(9):1165–1175
Suwanlert S (1975) A study of kratom eaters in Thailand. Bull Narc 27(3):21–27
Roche K (2008) Kratom: a case of a legal high. Clin Toxicol 46(7):598
Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM (2010) Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol 6(4):424–426
Sheleg SV, Collins GB (2011) A coincidence of addiction to “Kratom” and severe primary hypothyroidism. J Addict Med 5(4):300–301
McWhirter L, Morris S (2010) A case report of inpatient detoxification after Kratom (Mitragyna speciosa) dependence. Eur Addict Res 16(4):229–231
Kapp FG, Maurer HH, Auwarter V, Winkelmann M, Hermanns-Clausen M (2011) Intrahepatic cholestasis following abuse of powdered Kratom (Mitragyna speciosa). J Med Toxicol 7(3):227–231
Kronstrand R, Roman M, Thelander G, Eriksson A (2011) Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 35(4):242–247
Philipp AA, Wissenbach DK, Weber AA, Zapp J, Zoerntlein SW, Kanogsunthornrat J et al (2010) Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. Anal Bioanal Chem 396(7):2379–2391
Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH (2010) Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry. J Mass Spectrom 45(11):1344–1357
Philipp AA, Meyer MR, Wissenbach DK, Weber AA, Zoerntlein SW, Zweipfenning PG et al (2011) Monitoring of Kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem 400(1):127–135
Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH (2011) Metabolism studies of the Kratom alkaloid speciociliatine, a diastereomer of the main alkaloid mitragynine, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. Anal Bioanal Chem 399(8):2747–2753
Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH (2011) Metabolism studies of the Kratom alkaloids mitraciliatine and isopaynantheine, diastereomers of the main alkaloids mitragynine and paynantheine, in rat and human urine using liquid chromatography-linear ion trap-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(15–16):1049–1055
Kikura-Hanajiri R (2009) Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant “Kratom” (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol 27:67–74
Vuppala P, Boddu S, Furr E, McCurdy C, Avery B (2011) Simple, sensitive, high-throughput method for the quantification of mitragynine in rat plasma using UPLC-MS and its application to an intravenous pharmacokinetic study. Chromtographia 74(9–10):703–710
Kelly BC (2011) Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoact Drug 43(1):46–54
European Monitoring Centre for Drugs and Drug Addiction (2011) Salvia divinorum. http://www.emcdda.europa.eu/publications/drug-profiles/salvia. Accessed 20 Aug 2011
Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111(3):250–256
US Drug Enforcement Administration (2011) Salvia divinorum—drug fact sheet. http://www.justice.gov/dea/pubs/abuse/drug_data_sheets/Salvia.pdf. Accessed 20 Aug 2011
US Drug Enforcement Administration (2008) Salvia divinorum and salvorin A. http://www.justice.gov/dea/concern/salvia_divinorum_one_pager.pdf. Accessed 20 Aug 2011
Schwartz A (2010) Bong hit gives Miley Cyrus the giggles. http://www.people.com/people/article/0,,20448642,00.html. Accessed 11 Aug 2011
Sulzberger A, Medina J (2011) Shooting suspect had been known to use potent, and legal, hallucinogen. http://www.nytimes.com/2011/01/18/us/18salvia.html. Accessed 20 Aug 2011
Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S et al (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99(18):11934–11939
McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ (2006) Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83(1):109–113
Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER et al (2005) Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem 48(15):4765–4771
Capasso R, Borrelli F, Capasso F, Siebert DJ, Stewart DJ, Zjawiony JK et al (2006) The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 18(1):69–75
Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH (2005) Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16(8):627–633
Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179(3):551–558
Hanes KR (2001) Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21(6):634–635
Braida D, Capurro V, Zani A, Rubino T, Vigano D, Parolaro D et al (2009) Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 157(5):844–853
Grilli M, Neri E, Zappettini S, Massa F, Bisio A, Romussi G et al (2009) Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals. Neuropharmacology 57(5–6):523–530
Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53–56
Schmidt M, Schmidt M, Butelman E, Harding W, Tidgewell K, Murry D et al (2005) Pharmokinetics of the plant-derived k-opioid hallucinogen salvinorin a in nonhuman primates. Synapse 58:208–210
Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H (2009) In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 39(5):391–398
Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ et al (2005) Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 818(2):221–225
Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63(2):316–347
Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115(1–2):150–155
Baggott M, Erowid E, Erowid F (2004) A survey of Salvia divinorum users. Erowid Extracts 6:12–14
Lange JE, Daniel J, Homer K, Reed MB, Clapp JD (2010) Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108(1–2):138–140
Przekop P, Lee T (2009) Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 166(7):832
Vohra R, Seefeld A, Cantrell FL, Clark RF (2011) Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med 40(6):643–650
Aviello G, Borrelli F, Guida F, Romano B, Lewellyn K, De Chiaro M et al (2011) Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo. J Mol Med (Berl) 89(9):891–902
Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R et al (2005) Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 19(12):1649–1656
Erowid Vaults (2011) Methoxetamine. http://www.erowid.org/chemicals/methoxetamine/. Accessed 18 July 2011
Yipeng Chemical (2011) Encyclopedia of methoxetamine. http://www.yipengchem.com/es/tech_OTN-028025.htm. Accessed 19 July 2011
Kaupang A, Gorbitz CH, Hansen T (2010) tert-Butyl 4-(2-diazo-acet-yl)piperazine-1-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online 66(Pt 6):o1299
Erowid Experience Vaults—Methoxetamine (2011) First time for and experienced K lover. http://www.erowid.org/experiences/exp.php?ID=88687. Accessed 17 July 2011
Erowid Experience Vaults—Methoxetamine (2011) A rather promising compound. http://www.erowid.org/experiences/exp.php?ID=91374. Accessed 18 July 2011
Erowid Experience Vaults—Methoxetamine (2011) Suspected overdose, be careful. http://www.erowid.org/experiences/exp.php?ID=91291. Accessed 19 July 2011
Morris H (2011) Interview with a ketamine chemist, or to be more precise, an arylcyclohexylamine chemist. Vice Magazine
Ward J, Rhyee S, Plansky J (2011) Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 49(9):874–875
Drug Enforcement Agency (2010) Drugs and chemicals of concern: N-benzylpiperazine. http://www.deadiversion.usdoj.gov/drugs_concern/bzp_tmp/bzp_tmp.htm. Accessed 7 Aug 2011
Dick D, Torrance C (2010) MixMag drugs survey. Mix Mag 225:44–53
Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K (1987) Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 39(2):203–211
Staack RF (2007) Piperazine designer drugs of abuse. Lancet 369(9571):1411–1413
Bye C, Munro-Faure AD, Peck AW, Young PA (1973) A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 6(3):163–169
Staack RF, Maurer HH (2005) Metabolism of designer drugs of abuse. Curr Drug Metab 6(3):259–274
Antia U, Tingle MD, Russell BR (2009) Metabolic interactions with piperazine-based ‘party pill’ drugs. J Pharm Pharmacol 61(7):877–882
Campbell H, Cline W, Evans M, Lloyd J, Peck AW (1973) Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 6(3):170–176
Gee P, Richardson S, Woltersdorf W, Moore G (2005) Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 118(1227):U1784
Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R et al (2010) Purchasing ‘legal highs’ on the Internet—is there consistency in what you get? QJM: Monthly J Assoc Physician 103(7):489–493
de Boer D, Bosman IJ, Hidvegi E, Manzoni C, Benko AA, dos Reys LJ et al (2001) Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 121(1–2):47–56
Elliott S, Smith C (2008) Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 32(2):172–177
Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J et al (2007) Collapse, reported seizure—and an unexpected pill. Lancet 369(9571):1490
Winstock AR, Ramsey JD (2010) Legal highs and the challenges for policy makers. Addiction 105(10):1685–1687
Boyer EW, Shannon M, Hibberd PL (2005) The Internet and psychoactive substance use among innovative drug users. Pediatrics 115(2):302–305
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosenbaum, C.D., Carreiro, S.P. & Babu, K.M. Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. J. Med. Toxicol. 8, 15–32 (2012). https://doi.org/10.1007/s13181-011-0202-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-011-0202-2